A consumer patch offers neither a proven route across the skin nor a verified dose, which is the core reason clinicians do not treat patches as equivalent to a regulated GLP-1 medication
Higher predisposition to adverse effects Additionally, people who had previously used gastrointestinal medications -- which may indicate they are more vulnerable to the common adverse gastrointestinal side-effects reported by GLP1-RA users, such as nausea, vomiting, diarrhea -- were 9% more likely to discontinue semaglutide within the first year
The 13% who discontinued did so primarily during weeks 4-10 when gastrointestinal side effects peak
If more than 4 days have passed, skip it and resume your regular schedule
For a 180 lb (82 kg) patient that is roughly 82122 g/day
To continue the medication, we will need to submit a new prior authorization showing that the medication is working effectively and that you are making progress toward your health goals